Evenamide as add-on treatment for patients with chronic schizophrenia not responding adequately to their current antipsychotic medication: results of a potentially pivotal, phase II/III, international, randomized, double blind, placebo-controlled trial

Ravi Anand

[P500] Evenamide as add-on treatment for patients with chronic schizophrenia not responding adequately to their current antipsychotic medication: results of a potentially pivotal, phase II/III, international, randomized, double blind, placebo-controlled trial

*Ravi Anand¹, Alessio Turolla², Giovanni Chinellato², Rodolfo Giuliani², Richard Hartman³ (1. Anand Pharma Consulting, 2. Newron Pharmaceuticals SpA, 3. NeurWrite LLC)

Keywords:Schizophrenia, Phase 2/3 trial, glutamate modulation, add-on treatment, evenamide

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.

Presentation information

Schizophrenia 5 - Clinical (3)

[P500] Evenamide as add-on treatment for patients with chronic schizophrenia not responding adequately to their current antipsychotic medication: results of a potentially pivotal, phase II/III, international, randomized, double blind, placebo-controlled trial

Password